Skip to main content
N

NOVA EYE MEDICAL LIMITED — Investor Relations & Filings

Ticker · EYE ISIN · AU0000094252 ASX Manufacturing
Filings indexed 716 across all filing types
Latest filing 2024-12-16 Regulatory Filings
Country AU Australia
Listing ASX EYE

About NOVA EYE MEDICAL LIMITED

https://www.nova-eye.com

Nova Eye Medical Limited is a medical technology company focused on the development, manufacture, and commercialization of advanced ophthalmic treatment technologies. The company specializes in solutions for glaucoma and age-related macular degeneration (AMD). Its primary product portfolio includes the iTrack™ portfolio of canaloplasty microcatheters, designed for minimally invasive glaucoma surgery (MIGS) to restore the eye's natural outflow pathway. Additionally, the company offers the Molteno3® glaucoma drainage device for complex glaucoma cases. Nova Eye Medical is also advancing 2RT®, a proprietary nanosecond laser therapy intended to treat early-stage AMD by stimulating a biological healing response in the retina. The company serves a global market of ophthalmic surgeons and specialists, providing clinical-stage and commercialized tools to improve patient outcomes in vision-threatening conditions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - EYE 7 pages 19.9KB
Regulatory Filings
2024-12-16 English
Notification regarding unquoted securities - EYE 6 pages 18.7KB
Regulatory Filings
2024-11-27 English
Change of Director's Interest Notice 2 pages 254.2KB
Regulatory Filings
2024-11-27 English
Notification of cessation of securities - EYE 4 pages 14.8KB
Regulatory Filings
2024-11-26 English
Change of Director's Interest Notice 2 pages 253.8KB
Regulatory Filings
2024-11-26 English
2024 AGM presentation 19 pages 1.5MB
Regulatory Filings
2024-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.